After Novartis, Glenmark in diabetes drug patent violation case
New Delhi: Pharma firm MSD, the India affiliate of US-based Merck & Co, on Tuesday said it has sued Mumbai-based Glenmark for infringing on its patents for two diabetes drugs Januvia and Janumet.
"We have filed a suit in the hon’ble Delhi High Court against Glenmark for patent violation of our drugs JANUVIA and JANUMET," a MSD Spokesperson said in a statement.
MSD said: "We are disappointed in Glenmark's decision to introduce products that directly infringe upon our intellectual property."
The MSD action comes a day after Swiss drugmaker Novartis AG lost a landmark court ruling over patent protection for its cancer treatment, Glivec.
"We believe our patents for JANUVIA and JANUMET are valid and enforceable and will vigorously defend them," the MSD spokesperson said.
MSD holds an Indian patent on sitagliptin, a chemical compound sold under the Januvia and Janumet brands.
"As an innovative pharmaceutical company, protection of our intellectual property is vital to ensuring that we continue to assume the tremendous monetary risks associated with the discovery of innovative medicines," MSD said.
When contacted a Glenmark spokesperson said in a statement: "Glenmark is a responsible company and has launched the products after due diligence and research."